Not intended for human or animal injection, therapeutic, or diagnostic use
For CY 2026, the OPPS payment rates were proposed based on available CY 2024 claims data as the available single frequency claims exceed the 100 claims threshold generally used for our universal low volume policy
However, AOD 9604 therapy is not recommended for: Pregnant or breastfeeding individuals People with cancer history (because of the need for safety clearance due to the growth aspect) Individuals with uncontrolled chronic disease unless cleared by physician Always speak to your licensed healthcare provider before proceeding with peptide therapy to determine if its a fit for your health status and goals
However, persistently high serum B12 levels warrant medical investigation, as they may indicate liver disease, kidney dysfunction, or haematological disorders rather than simple overconsumption
Peptide Therapy & FDA Regulatory Status 2026 The peptide therapy landscape is changing rapidly, and we believe our patients deserve a straight, accurate explanation of where each therapy stands today
